CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Petros Pharmaceuticals, Inc. - PTPI CFD

1.45
1.4%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.43
Open* 1.4
1-Year Change* -1.41%
Day's Range* 1.4 - 1.48
52 wk Range 0.37-5.20
Average Volume (10 days) 76.89K
Average Volume (3 months) 2.81M
Market Cap 8.83M
P/E Ratio -100.00K
Shares Outstanding 20.71M
Revenue 4.33M
EPS -1.51
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 1.45 0.06 4.32% 1.39 1.49 1.38
Mar 27, 2024 1.43 0.00 0.00% 1.43 1.48 1.37
Mar 26, 2024 1.52 -0.02 -1.30% 1.54 1.55 1.45
Mar 25, 2024 1.55 0.08 5.44% 1.47 1.56 1.44
Mar 22, 2024 1.47 -0.04 -2.65% 1.51 1.53 1.41
Mar 21, 2024 1.48 0.09 6.47% 1.39 1.51 1.34
Mar 20, 2024 1.39 0.03 2.21% 1.36 1.40 1.32
Mar 19, 2024 1.42 -0.06 -4.05% 1.48 1.64 1.39
Mar 18, 2024 1.45 -0.03 -2.03% 1.48 1.56 1.43
Mar 15, 2024 1.50 0.14 10.29% 1.36 1.55 1.36
Mar 14, 2024 1.35 0.04 3.05% 1.31 1.38 1.28
Mar 13, 2024 1.41 -0.04 -2.76% 1.45 1.46 1.40
Mar 12, 2024 1.46 -0.07 -4.58% 1.53 1.53 1.45
Mar 11, 2024 1.54 -0.04 -2.53% 1.58 1.62 1.53
Mar 8, 2024 1.60 0.10 6.67% 1.50 1.62 1.50
Mar 7, 2024 1.48 -0.07 -4.52% 1.55 1.55 1.48
Mar 6, 2024 1.57 0.05 3.29% 1.52 1.59 1.45
Mar 5, 2024 1.49 -0.04 -2.61% 1.53 1.58 1.44
Mar 4, 2024 1.58 0.00 0.00% 1.58 1.62 1.53
Mar 1, 2024 1.64 -0.06 -3.53% 1.70 1.71 1.60

Petros Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018
Total revenue 7.81126 9.55947 15.5772 14.0512
Revenue 7.81126 9.55947 15.5772 14.0512
Cost of Revenue, Total 1.59957 4.04647 7.42711 2.41583
Gross Profit 6.21169 5.513 8.15006 11.6354
Total Operating Expense 25.8593 26.8415 34.8894 39.6899
Selling/General/Admin. Expenses, Total 15.5932 15.675 19.7272 11.2618
Depreciation / Amortization 6.87799 6.66044 5.29111 8.06499
Unusual Expense (Income) 0 2.44393 17.9473
Operating Income -18.048 -17.282 -19.3122 -25.6387
Interest Income (Expense), Net Non-Operating 9.06134 -4.73088 -13.845 -11.8568
Other, Net 0 5.00947
Net Income Before Taxes -8.98668 -22.0129 -33.1572 -32.4861
Net Income After Taxes -8.98668 -20.5859 -32.5113 -32.4727
Net Income Before Extra. Items -8.98668 -20.5859 -32.5113 -32.4727
Net Income -8.98668 -20.5859 -32.5113 -32.4727
Income Available to Common Excl. Extra. Items -8.98668 -20.5859 -32.5113 -32.4727
Income Available to Common Incl. Extra. Items -8.98668 -20.5859 -32.5113 -32.4727
Diluted Net Income -8.98668 -20.5859 -32.5113 -32.4727
Diluted Weighted Average Shares 10.8898 9.70766 9.70774 9.70774
Diluted EPS Excluding Extraordinary Items -0.82524 -2.12059 -3.34901 -3.34503
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.82524 -2.12059 -3.18537 -2.14334
Research & Development 1.78849 0.45964
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 2.46517 7.81126 2.14517 2.45765 4.07561
Revenue 2.46517 7.81126 2.14517 2.45765 4.07561
Cost of Revenue, Total 0.47234 1.59957 0.31916 0.39329 0.64339
Gross Profit 1.99283 6.21169 1.82601 2.06436 3.43222
Total Operating Expense 2.94637 25.8593 5.74179 6.73834 6.27311
Selling/General/Admin. Expenses, Total 3.89774 15.5932 3.41322 4.11617 3.88172
Research & Development 0.40536 1.78849 0.28058 0.50005 0.01918
Depreciation / Amortization 1.56087 6.87799 1.72883 1.72883 1.72883
Operating Income -0.4812 -18.048 -3.59662 -4.28069 -2.1975
Interest Income (Expense), Net Non-Operating 0.30697 9.06134 1.90206 2.17447 5.20659
Net Income Before Taxes -0.17422 -8.98668 -1.69455 -2.10622 3.00908
Net Income After Taxes -0.17422 -8.98668 -1.6969 -2.11292 3.00908
Net Income Before Extra. Items -0.17422 -8.98668 -1.6969 -2.11292 3.00908
Net Income -0.17422 -8.98668 -1.6969 -2.11292 3.00908
Income Available to Common Excl. Extra. Items -0.17422 -8.98668 -1.6969 -2.11292 3.00908
Income Available to Common Incl. Extra. Items -0.17422 -8.98668 -1.6969 -2.11292 3.00908
Diluted Net Income -0.17422 -8.98668 -1.6969 -2.11292 3.00908
Diluted Weighted Average Shares 20.6847 10.8898 9.8266 9.80231 9.75469
Diluted EPS Excluding Extraordinary Items -0.00842 -0.82524 -0.17268 -0.21555 0.30848
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.17231 -0.82524 -0.17268 -0.21555 0.30848
Unusual Expense (Income) -3.38994
  • Annual
  • Quarterly
2021 2020 2019 2018
Total Current Assets 30.5427 25.9051 12.0875 15.808
Cash and Short Term Investments 23.8476 17.1443 2.14814 4.20121
Cash 23.8476 17.1397 2.14581 2.79413
Short Term Investments 0 0.00458 0.00233 1.40708
Total Receivables, Net 2.45539 5.15297 2.60513 3.51207
Accounts Receivable - Trade, Net 2.45539 5.15297 2.60513 3.51207
Total Inventory 0.51965 0.76053 2.20443 6.49024
Prepaid Expenses 1.58132 1.42796 3.19392 1.46502
Other Current Assets, Total 2.13876 1.41933 1.9359 0.13947
Total Assets 67.3901 69.854 58.3663 66.8861
Property/Plant/Equipment, Total - Net 0.52495 0.64379 0.74208 0
Goodwill, Net 0 2.44393
Intangibles, Net 25.2931 32.1609 38.8111 44.1005
Other Long Term Assets, Total 11.0293 11.1443 6.72556 4.53364
Total Current Liabilities 30.9801 41.894 41.1043 38.5409
Accounts Payable 4.55797 5.60956 3.77644 1.7522
Accrued Expenses 23.5402 26.7291 23.6406 17.076
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 7.17503 6.68194 19.341
Other Current Liabilities, Total 2.88194 2.38032 7.00536 0.37166
Total Liabilities 31.8451 52.385 50.3471 68.5674
Total Long Term Debt 0 0 7.06103 27.8911
Long Term Debt 0 7.06103 27.8911
Deferred Income Tax 1.43217 2.07803
Other Liabilities, Total 0.86502 10.4909 0.74955 0.0574
Total Equity 35.545 17.469 8.01922 -1.68127
Preferred Stock - Non Redeemable, Net 0 20.0182 0
Common Stock 0.00207 0.00097 29.1172 0
Retained Earnings (Accumulated Deficit) -70.6888 -61.7021 -41.1162 -1.68127
Total Liabilities & Shareholders’ Equity 67.3901 69.854 58.3663 66.8861
Total Common Shares Outstanding 20.6847 9.70766 9.70774 9.70774
Additional Paid-In Capital 106.232 79.1702
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 26.8381 30.5427 13.3543 16.2341 23.9637
Cash and Short Term Investments 17.6719 23.8476 8.13518 11.0312 14.5713
Cash 17.6719 23.8476 8.13518 11.0312 14.5667
Short Term Investments 0 0 0 0.00458
Total Receivables, Net 3.74078 2.45539 1.95242 2.02092 6.1942
Accounts Receivable - Trade, Net 3.74078 2.45539 1.95242 2.02092 6.1942
Total Inventory 1.94287 0.51965 0.51848 0.43923 0.56086
Prepaid Expenses 1.37845 1.58132 0.83102 1.30183 1.23569
Other Current Assets, Total 2.10414 2.13876 1.91721 1.4409 1.40162
Total Assets 55.8642 67.3901 52.0353 56.6702 66.154
Property/Plant/Equipment, Total - Net 0.49444 0.52495 0.55465 0.58356 0.61144
Intangibles, Net 23.7348 25.2931 26.9821 28.7084 30.4347
Other Long Term Assets, Total 4.79677 11.0293 11.1443 11.1443 11.1443
Total Current Liabilities 10.2887 30.9801 33.5006 34.4899 40.2204
Accounts Payable 3.70033 4.55797 5.31234 2.59789 5.27628
Accrued Expenses 5.29205 23.5402 21.3846 25.2862 26.8111
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.72398 0 1.74075 3.42538 5.06126
Other Current Liabilities, Total 0.57239 2.88194 5.06293 3.1805 3.07176
Total Liabilities 20.1376 31.8451 34.1883 37.1795 45.2309
Total Long Term Debt 9.47778 0 0 0 0
Other Liabilities, Total 0.37105 0.86502 0.68775 2.68957 5.01051
Total Equity 35.7266 35.545 17.847 19.4907 20.9231
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.00207 0.00207 0.00098 0.00098 0.00098
Additional Paid-In Capital 106.588 106.232 80.3489 80.2957 79.6152
Retained Earnings (Accumulated Deficit) -70.863 -70.6888 -62.5029 -60.806 -58.6931
Total Liabilities & Shareholders’ Equity 55.8642 67.3901 52.0353 56.6702 66.154
Total Common Shares Outstanding 20.6847 20.6847 9.8266 9.8266 9.79826
Long Term Debt 9.47778
  • Annual
  • Quarterly
2021 2020 2019 2018
Net income/Starting Line -8.98668 -20.5859 -32.5113 -32.4727
Cash From Operating Activities -11.862 -15.3053 2.53248 8.02077
Amortization 6.65022 5.2894 8.06499
Deferred Taxes 0 -1.43217 -0.64587 -0.00694
Non-Cash Items -8.05974 5.65288 17.3305 27.5022
Cash Interest Paid 0.42182 1.1914 2.04097 2.73842
Changes in Working Capital -1.69361 -5.60055 13.068 4.93318
Cash From Investing Activities 0 -0.00463 -0.07154 -1.87566
Capital Expenditures 0 -0.00463 -0.07154 -1.87566
Cash From Financing Activities 18.5699 30.3038 -3.10925 -2.54776
Issuance (Retirement) of Stock, Net 25.7574 0.02055 2.90401 0
Issuance (Retirement) of Debt, Net -7.18753 8.78391 -6.01326 -2.54776
Net Change in Cash 6.70788 14.9939 -0.64831 3.59734
Cash From Operating Activities 6.87799 0.01022 0.0017
Financing Cash Flow Items 0 21.4994
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -0.17422 -8.98668 -0.80073 0.89616 3.00908
Cash From Operating Activities -5.2757 -11.862 -3.55773 -2.34637 -0.44658
Cash From Operating Activities 1.56087 6.87799 5.18649 3.45766 1.72883
Deferred Taxes 0 0 0 0
Non-Cash Items -3.57792 -8.05974 -8.38788 -6.82428 -4.84613
Cash Interest Paid 0 0.42182 0.39358 0.3095 0.17668
Changes in Working Capital -3.08443 -1.69361 0.44439 0.1241 -0.33837
Cash From Investing Activities 0 0 0 0
Capital Expenditures 0 0 0 0
Cash From Financing Activities -0.9 18.5699 -5.44678 -3.76215 -2.1264
Issuance (Retirement) of Debt, Net -0.9 -7.18753 -5.44678 -3.76215 -2.1264
Net Change in Cash -6.1757 6.70788 -9.00451 -6.10852 -2.57298
Financing Cash Flow Items 0 0 0
Issuance (Retirement) of Stock, Net 25.7574

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Petros Pharmaceuticals, Inc. Company profile

About Petros Pharmaceuticals Inc

Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Petros Pharmaceuticals Inc revenues totaled $8.7M. Net loss totaled to $801K.

Industry: Biotechnology & Medical Research (NEC)

1185 Avenue Of The Americas, 3Rd Floor
Suite 570
10036

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,404.15 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.64 Price
+1.850% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading